AR105738A1 - Compuesto de tetrahidrooxepinopiridina - Google Patents
Compuesto de tetrahidrooxepinopiridinaInfo
- Publication number
- AR105738A1 AR105738A1 ARP160102537A ARP160102537A AR105738A1 AR 105738 A1 AR105738 A1 AR 105738A1 AR P160102537 A ARP160102537 A AR P160102537A AR P160102537 A ARP160102537 A AR P160102537A AR 105738 A1 AR105738 A1 AR 105738A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- ring
- halo
- compound
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El compuesto de tetrahidrooxepinopiridina de la presente tiene una actividad PAM sobre un receptor a7 nACh, como un agente para la prevención o el tratamiento de demencia, deterioro cognitivo, esquizofrenia, enfermedad de Alzheimer, CIAS, síntomas negativos de esquizofrenia, enfermedades inflamatorias o dolor. Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales, (en la fórmula, R¹ es H o alquilo inferior; R² es H o CN; cualquiera de G¹, G² y G³ es O, y los otros dos de G¹, G² y G³ son CH₂; el anillo A es arilo, o heteroarilo que contiene nitrógeno; el anillo B es amino cíclico; R³ y R⁴ son iguales o diferentes entre sí, y son H, halógeno, alquilo inferior, -alquileno inferior-OH, halo-alquilo inferior, -O-alquilo inferior, -O-halo-alquilo inferior, cicloalquilo, CN, OH, -N(alquilo inferior)₂, o -C(=O)NH₂; R⁵, R⁶, R⁷ y R⁸ son iguales o diferentes entre sí, y son H, halógeno, alquilo inferior, halo-alquilo inferior, -O-alquilo inferior, o CN, o en el caso donde R⁵ y R⁶ están enlazados al mismo átomo de carbono, R⁵ y R⁶ pueden formar cicloalcano o éter cíclico junto con el átomo de carbono, y pueden formar un anillo espiro junto con el anillo B, o el anillo B puede formar 6,7-dihidro[1,3]oxazolo[4,5-c]piridin-5(4H)-ilo junto con R⁵ y R⁶.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015162320 | 2015-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105738A1 true AR105738A1 (es) | 2017-11-01 |
Family
ID=58052257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102537A AR105738A1 (es) | 2015-08-19 | 2016-08-18 | Compuesto de tetrahidrooxepinopiridina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9670219B2 (es) |
| EP (1) | EP3345909B1 (es) |
| JP (1) | JP6787320B2 (es) |
| KR (1) | KR102614279B1 (es) |
| CN (1) | CN107922426B (es) |
| AR (1) | AR105738A1 (es) |
| AU (1) | AU2016308406A1 (es) |
| CA (1) | CA2995554C (es) |
| CO (1) | CO2018002472A2 (es) |
| EA (1) | EA034794B1 (es) |
| ES (1) | ES2812246T3 (es) |
| HK (1) | HK1251574A1 (es) |
| IL (1) | IL257450A (es) |
| MX (1) | MX2018002118A (es) |
| PH (1) | PH12018500297A1 (es) |
| PL (1) | PL3345909T3 (es) |
| PT (1) | PT3345909T (es) |
| SG (1) | SG11201801193QA (es) |
| TW (1) | TW201722962A (es) |
| WO (1) | WO2017030171A1 (es) |
| ZA (1) | ZA201801098B (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010020672A1 (en) * | 2008-08-21 | 2010-02-25 | Neurosearch A/S | Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| MY161236A (en) | 2011-02-25 | 2017-04-14 | Janssen Pharmaceutica Nv | (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr |
| AR086791A1 (es) * | 2011-07-01 | 2014-01-22 | Lundbeck & Co As H | Moduladores alostericos positivos del receptor de acetilcolina nicotinico |
| US20130005743A1 (en) * | 2011-07-01 | 2013-01-03 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
-
2016
- 2016-08-18 EP EP16837160.7A patent/EP3345909B1/en active Active
- 2016-08-18 TW TW105126427A patent/TW201722962A/zh unknown
- 2016-08-18 SG SG11201801193QA patent/SG11201801193QA/en unknown
- 2016-08-18 PT PT168371607T patent/PT3345909T/pt unknown
- 2016-08-18 WO PCT/JP2016/074145 patent/WO2017030171A1/ja active Application Filing
- 2016-08-18 AU AU2016308406A patent/AU2016308406A1/en not_active Abandoned
- 2016-08-18 EA EA201890514A patent/EA034794B1/ru not_active IP Right Cessation
- 2016-08-18 JP JP2017535563A patent/JP6787320B2/ja active Active
- 2016-08-18 MX MX2018002118A patent/MX2018002118A/es active IP Right Grant
- 2016-08-18 AR ARP160102537A patent/AR105738A1/es unknown
- 2016-08-18 ES ES16837160T patent/ES2812246T3/es active Active
- 2016-08-18 CN CN201680048575.8A patent/CN107922426B/zh active Active
- 2016-08-18 KR KR1020187004555A patent/KR102614279B1/ko active IP Right Grant
- 2016-08-18 PL PL16837160T patent/PL3345909T3/pl unknown
- 2016-08-18 CA CA2995554A patent/CA2995554C/en active Active
- 2016-09-07 US US15/258,241 patent/US9670219B2/en active Active
-
2018
- 2018-02-09 PH PH12018500297A patent/PH12018500297A1/en unknown
- 2018-02-11 IL IL257450A patent/IL257450A/en unknown
- 2018-02-16 ZA ZA2018/01098A patent/ZA201801098B/en unknown
- 2018-03-06 CO CONC2018/0002472A patent/CO2018002472A2/es unknown
- 2018-08-31 HK HK18111189.8A patent/HK1251574A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018003171A2 (pt) | 2018-09-25 |
| MX2018002118A (es) | 2018-06-18 |
| US9670219B2 (en) | 2017-06-06 |
| WO2017030171A1 (ja) | 2017-02-23 |
| KR20180037983A (ko) | 2018-04-13 |
| ZA201801098B (en) | 2019-04-24 |
| CO2018002472A2 (es) | 2018-05-31 |
| JPWO2017030171A1 (ja) | 2018-06-07 |
| KR102614279B1 (ko) | 2023-12-18 |
| EA034794B1 (ru) | 2020-03-23 |
| HK1251574A1 (zh) | 2019-02-01 |
| IL257450A (en) | 2018-04-30 |
| ES2812246T3 (es) | 2021-03-16 |
| US20170050973A1 (en) | 2017-02-23 |
| CA2995554A1 (en) | 2017-02-23 |
| EP3345909A1 (en) | 2018-07-11 |
| TW201722962A (zh) | 2017-07-01 |
| PT3345909T (pt) | 2020-07-29 |
| PH12018500297A1 (en) | 2018-08-13 |
| JP6787320B2 (ja) | 2020-11-18 |
| CN107922426B (zh) | 2021-03-26 |
| EA201890514A1 (ru) | 2018-07-31 |
| CA2995554C (en) | 2023-06-27 |
| CN107922426A (zh) | 2018-04-17 |
| EP3345909B1 (en) | 2020-06-17 |
| AU2016308406A1 (en) | 2018-03-08 |
| EP3345909A4 (en) | 2019-04-10 |
| PL3345909T3 (pl) | 2020-10-19 |
| SG11201801193QA (en) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000666A1 (es) | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. | |
| CO2019003349A2 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| CL2017000381A1 (es) | Nuevos compuestos de spiro[3h-indol-3,2'-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR099785A1 (es) | Compuestos heteroarilos y su uso como medicamentos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR098912A1 (es) | Inhibidores de syk | |
| UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
| UY39887A (es) | (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7 | |
| AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
| AR102227A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CR20170003A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| PE20160201A1 (es) | Bencil-1h-pirazol[3,4-b]piridinas y su uso | |
| AR097932A1 (es) | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) | |
| AR101395A1 (es) | Derivados de indolizina y su uso en enfermedades neurodegenerativas | |
| AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) | |
| AR097739A1 (es) | Imidazo[1,2-a]piridina-7-aminas | |
| CL2021000296A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad. | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |